CEO Newsletter 3, 2021
”Retreading old footsteps has never been a driving force for Fluicell” In the third issue of the CEO…
”Retreading old footsteps has never been a driving force for Fluicell” In the third issue of the CEO…
We are launching Biozone 6, Fluicell’s new innovation for single-cell pharmacology that lets you perform drug testing and…
Biopixlar’s microfluidic technology is ideal for printing even the most sensitive cell types. Using cells received from Dr….
“Building human tissues cell by cell”. In an interview with Di Hållbart Näringsliv, Fluicell’s CEO Victoire Viannay talks…
“Biopixlar is a high-resolution bioprinting platform that uses a proprietary molecular cell-binding process and open volume microfluidics technology…
Biozone 6™ is a new concept for direct single-cell pharmacology from Fluicell that lets users generate dose-response curves…
“2020 was a challenging but very successful year for Fluicell. In 2021, it is time to really pick…
How did the first life on earth emerge? The one who is asking this difficult question is Professor…
I find biology very fascinating in its own diverse complexity and in the way it presents creative solutions…